As the popularity of Ozempic—a diabetes drug widely used off-label for weight loss—continues to soar, new concerns are emerging about its safety for breastfeeding mothers. Medical professionals are urging caution, as there is limited research on how semaglutide, the active ingredient in Ozempic, may affect infants through breast milk.
Why Is Ozempic Gaining Attention?
Originally developed to manage type 2 diabetes, Ozempic has become a sought-after solution for weight loss, thanks to its appetite-suppressing effects. However, its rapid rise in popularity has outpaced research into its long-term safety, particularly for vulnerable groups such as pregnant and breastfeeding women.
What Do Experts Say?
Healthcare providers are advising new mothers to avoid Ozempic while breastfeeding due to the lack of conclusive data. "We simply don’t know enough about how semaglutide transfers into breast milk or its potential impact on a baby’s development," says Dr. Emily Carter, a leading endocrinologist.
Potential Risks for Infants
- Unknown effects on infant growth and metabolism
- Possible disruption to blood sugar regulation
- Lack of clinical trials involving breastfeeding women
Alternative Approaches for Postpartum Weight Loss
For mothers looking to shed pregnancy weight safely, experts recommend:
- Balanced nutrition and hydration
- Gradual, moderate exercise
- Consulting a dietitian for personalised advice
Until further studies are conducted, the consensus remains clear: breastfeeding mothers should prioritise caution and explore safer weight management options.
